Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Liabilities and Shareholders Equity (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $69.3 billion as the latest value for Q3 2025.

  • Quarterly Liabilities and Shareholders Equity rose 1.99% to $69.3 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $137.4 billion through Sep 2025, up 101.63% year-over-year, with the annual reading at $69.3 billion for FY2025, 1.99% up from the prior year.
  • Liabilities and Shareholders Equity hit $69.3 billion in Q3 2025 for Universe Pharmaceuticals, up from $68.0 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $69.3 billion in Q3 2025 to a low of $41.7 million in Q3 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $27.5 billion across 5 years, with a median of $70.1 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 29.92% in 2023 and later skyrocketed 162762.16% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $70.1 million in 2021, then dropped by 15.12% to $59.5 million in 2022, then dropped by 29.92% to $41.7 million in 2023, then surged by 162762.16% to $68.0 billion in 2024, then increased by 1.99% to $69.3 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for UPC at $69.3 billion in Q3 2025, $68.0 billion in Q3 2024, and $41.7 million in Q3 2023.